These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8959982)

  • 1. Pharmacology of selegiline.
    Gerlach M; Youdim MB; Riederer P
    Neurology; 1996 Dec; 47(6 Suppl 3):S137-45. PubMed ID: 8959982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline.
    Gerlach M; Desser H; Youdim MB; Riederer P
    J Neural Transm Suppl; 1996; 48():7-21. PubMed ID: 8988458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of monoamine oxidase type B in humans.
    Heinonen EH; Anttila MI; Karnani HL; Nyman LM; Vuorinen JA; Pyykkö KA; Lammintausta RA
    J Clin Pharmacol; 1997 Jul; 37(7):602-9. PubMed ID: 9243353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacological actions of l-deprenyl (selegiline) and other selective monoamine oxidase B inhibitors.
    Youdim MB; Finberg JP
    Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 2):725-33. PubMed ID: 7995014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites.
    Heinonen EH; Anttila MI; Lammintausta RA
    Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 2):742-9. PubMed ID: 7995016
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical actions of l-deprenyl (selegiline).
    Lange KW; Riederer P; Youdim MB
    Clin Pharmacol Ther; 1994 Dec; 56(6 Pt 2):734-41. PubMed ID: 7995015
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacokinetics and pharmacodynamics of selegiline. An update.
    Mahmood I
    Clin Pharmacokinet; 1997 Aug; 33(2):91-102. PubMed ID: 9260033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A new formulation of selegiline: improved bioavailability and selectivity for MAO-B inhibition.
    Clarke A; Brewer F; Johnson ES; Mallard N; Hartig F; Taylor S; Corn TH
    J Neural Transm (Vienna); 2003 Nov; 110(11):1241-55. PubMed ID: 14628189
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of selegiline (deprenyl) in the treatment of Parkinson's disease.
    Heinonen EH; Myllylä V
    Drug Saf; 1998 Jul; 19(1):11-22. PubMed ID: 9673855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.
    Lyytinen J; Kaakkola S; Ahtila S; Tuomainen P; Teräväinen H
    Mov Disord; 1997 Jul; 12(4):497-505. PubMed ID: 9251066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rationale for (-)deprenyl (selegiline) medication in Parkinson's disease and in prevention of age-related nigral changes.
    Knoll J
    Biomed Pharmacother; 1995; 49(4):187-95. PubMed ID: 7669938
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
    Youdim MB
    J Neural Transm Suppl; 1986; 22():91-105. PubMed ID: 3097263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neuroprotective actions of selegiline.
    Ebadi M; Sharma S; Shavali S; El Refaey H
    J Neurosci Res; 2002 Feb; 67(3):285-9. PubMed ID: 11813232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetic and pharmacodynamic properties of drugs used in the treatment of Parkinson's disease.
    Deleu D; Northway MG; Hanssens Y
    Clin Pharmacokinet; 2002; 41(4):261-309. PubMed ID: 11978145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic transformation plays a primary role in the psychostimulant-like discriminative-stimulus effects of selegiline [(R)-(-)-deprenyl].
    Yasar S; Justinova Z; Lee SH; Stefanski R; Goldberg SR; Tanda G
    J Pharmacol Exp Ther; 2006 Apr; 317(1):387-94. PubMed ID: 16352699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH; Chen JJ
    Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
    Knoll J
    Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rasagiline (TVP-1012): a new selective monoamine oxidase inhibitor for Parkinson's disease.
    Guay DR
    Am J Geriatr Pharmacother; 2006 Dec; 4(4):330-46. PubMed ID: 17296539
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.